No Data
Revenues Not Telling The Story For Sanbo Hospital Management Group Limited (SZSE:301293)
Sanbo Neuroscience (301293.SZ): The company is still evaluating relevant products related to the AI large model and has not yet integrated them.
On March 7, Gelonghui reported that Sanbo Neurosurgery (301293.SZ) stated on the investor interaction platform that in order to continuously improve the quality and efficiency of Medical Services, certain departments in some of Sanbo Neurosurgery's hospital locations are utilizing AI Asia Vets products and technologies. The company is still evaluating related products for the AI large model, which has not yet been integrated. The company reminds investors that Sanbo Neurosurgery is a medical group led by the investment, management, and Operation of hospitals, and its subordinate sites mainly provide comprehensive Medical Services focused on advanced neurosurgery for patients, serving as the application end of relevant intelligent products, without engaging in production and sales.
Sanbo Neuroscience (301293.SZ): The general manager has been changed to Xu Xiangying.
On March 4, Gelonghui reported that Sanbo Neuroscience (301293.SZ) announced that the Board of Directors recently received the resignation letter submitted by Mr. Zhang Yang. According to the company's Operation development and management needs, Mr. Zhang Yang resigned from the position of General Manager, originally set to last until the end of the term of the third Board of Directors. Mr. Zhang Yang currently Holds 21,815,703 shares, accounting for 10.59% of the company's total share capital. After resigning from the General Manager position, he will continue to serve as a Director, Chairman, and Chairman of the Board of Directors' Strategic Committee. The shares he Holds will continue to comply with the Company Law, Securities Law, and regulations of the China Securities Regulatory Commission.
Sanbo Hospital Management Group Limited's (SZSE:301293) Market Cap up CN¥473m Last Week, Benefiting Both Individual Investors Who Own 48% as Well as Insiders
Sanbo Neuroscience (301293.SZ): The company has not conducted specialized research in the field of amyotrophic lateral sclerosis.
On December 18, Gelonghui reported that Sanbo Neurosurgery (301293.SZ) stated on the investor interaction platform that it is a medical group primarily focused on the investment, management, and Operation of Hospitals, with its subsidiary facilities mainly providing comprehensive Medical Services centered on advanced neurosurgery. The company has not conducted specialized research in the area of amyotrophic lateral sclerosis.
Sanbo Neuroscience (301293.SZ): Some hospitals and departments are utilizing asia vets products and technology.
On December 10, Glonhui reported that Sanbo Neuroscience (301293.SZ) stated on the investor interaction platform that some departments in certain hospital branches are utilizing AI asia vets products and technologies. In order to continuously improve the quality and efficiency of medical services, the company is also advancing its information technology process. At the same time, it reminds investors that Sanbo Neuroscience is a medical group primarily focused on the investment, management, and operation of hospitals, with its branches mainly providing comprehensive medical services centered around advanced neurosurgery, serving as the application end for relevant asia vets products, and does not engage in the research and production of related intelligent products.
Revenues Not Telling The Story For Sanbo Hospital Management Group Limited (SZSE:301293) After Shares Rise 27%
